281 related articles for article (PubMed ID: 37305348)
1. Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.
Manta A; Kazanas S; Karamaroudis S; Gogas H; Ziogas DC
Oncol Res; 2022; 30(5):211-219. PubMed ID: 37305348
[TBL] [Abstract][Full Text] [Related]
2. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
Garmpi A; Garmpis N; Damaskos C; Valsami S; Spartalis E; Lavaris A; Patelis N; Margonis GA; Apostolou KG; Spartalis M; Andreatos N; Diamantis E; Tsivelekas K; Moschos MM; Nonni A; Tsourouflis G; Markatos K; Antoniou EA; Kontzoglou K; Nikiteas N; Dimitroulis D
J BUON; 2018; 23(4):846-861. PubMed ID: 30358185
[TBL] [Abstract][Full Text] [Related]
4. Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options.
Manou M; Kanakoglou DS; Loupis T; Vrachnos DM; Theocharis S; Papavassiliou AG; Piperi C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373187
[TBL] [Abstract][Full Text] [Related]
5. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies.
Pal D; Raj K; Nandi SS; Sinha S; Mishra A; Mondal A; Lagoa R; Burcher JT; Bishayee A
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345145
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.
Sanaei M; Kavoosi F
Iran J Pharm Res; 2021; 20(3):324-336. PubMed ID: 34903992
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
8. Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.
Zhang C; Li HX; Man Y; Jiang ZH; Yin P; Yu K
J Physiol Pharmacol; 2024 Apr; 75(2):117-122. PubMed ID: 38736259
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Shankar S; Srivastava RK
Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?
Koutsounas I; Giaginis C; Theocharis S
World J Gastroenterol; 2013 Feb; 19(8):1173-81. PubMed ID: 23482354
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Sanaei M; Kavoosi F
Adv Biomed Res; 2019; 8():63. PubMed ID: 31737580
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
[TBL] [Abstract][Full Text] [Related]
14. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
15. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Modifications by Probiotics in Colorectal Cancer.
Salek Farrokhi A; Mohammadlou M; Abdollahi M; Eslami M; Yousefi B
J Gastrointest Cancer; 2020 Sep; 51(3):754-764. PubMed ID: 31808058
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.
Zhou N; Xu W; Zhang Y
Drug Discov Ther; 2015 Jun; 9(3):147-55. PubMed ID: 26193935
[TBL] [Abstract][Full Text] [Related]
20. Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
